Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years

OBJECTIVES: This post hoc analysis of pooled data from two phase III studies (AD-301: NCT02118766; AD-302: NCT02118792) explored the efficacy and safety of crisaborole ointment, 2%, a nonsteroidal phosphodiesterase 4 inhibitor, for the treatment of mild-to-moderate atopic dermatitis (AD) in pediatri...

Descripción completa

Detalles Bibliográficos
Autores principales: Luger, Thomas A., Hebert, Adelaide A., Zaenglein, Andrea L., Silverberg, Jonathan I., Tan, Huaming, Ports, William C., Zielinski, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940811/
https://www.ncbi.nlm.nih.gov/pubmed/35292919
http://dx.doi.org/10.1007/s40272-021-00490-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940811/
https://www.ncbi.nlm.nih.gov/pubmed/35292919
http://dx.doi.org/10.1007/s40272-021-00490-y

Ejemplares similares